These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971 [No Abstract] [Full Text] [Related]
23. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Huang F; Greer A; Hurlburt W; Han X; Hafezi R; Wittenberg GM; Reeves K; Chen J; Robinson D; Li A; Lee FY; Gottardis MM; Clark E; Helman L; Attar RM; Dongre A; Carboni JM Cancer Res; 2009 Jan; 69(1):161-70. PubMed ID: 19117999 [TBL] [Abstract][Full Text] [Related]
24. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892 [TBL] [Abstract][Full Text] [Related]
25. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319 [TBL] [Abstract][Full Text] [Related]
26. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Phadke MS; Sini P; Smalley KS Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592 [TBL] [Abstract][Full Text] [Related]
27. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
28. Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors. Mangoni M; Sottili M; Salvatore G; Meattini I; Desideri I; Greto D; Loi M; Becherini C; Garlatti P; Delli Paoli C; Dominici L; Gerini C; Scoccianti S; Bonomo P; Silvano A; Beltrami G; Campanacci D; Livi L Radiat Res; 2018 Nov; 190(5):464-472. PubMed ID: 30067444 [TBL] [Abstract][Full Text] [Related]
29. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061 [TBL] [Abstract][Full Text] [Related]
30. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605 [TBL] [Abstract][Full Text] [Related]
31. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666 [TBL] [Abstract][Full Text] [Related]
32. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Manara MC; Perdichizzi S; Serra M; Pierini R; Benini S; Hattinger CM; Astolfi A; Bagnati R; D'Incalci M; Picci P; Scotlandi K Int J Oncol; 2005 Dec; 27(6):1605-16. PubMed ID: 16273217 [TBL] [Abstract][Full Text] [Related]
33. MicroRNA-7 directly targets insulin-like growth factor 1 receptor to inhibit cellular growth and glucose metabolism in gliomas. Wang B; Sun F; Dong N; Sun Z; Diao Y; Zheng C; Sun J; Yang Y; Jiang D Diagn Pathol; 2014 Nov; 9():211. PubMed ID: 25394492 [TBL] [Abstract][Full Text] [Related]
34. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components. Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249 [TBL] [Abstract][Full Text] [Related]
35. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825 [TBL] [Abstract][Full Text] [Related]
36. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition. Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743 [TBL] [Abstract][Full Text] [Related]
37. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. Gill SJ; Travers J; Pshenichnaya I; Kogera FA; Barthorpe S; Mironenko T; Richardson L; Benes CH; Stratton MR; McDermott U; Jackson SP; Garnett MJ PLoS One; 2015; 10(10):e0140988. PubMed ID: 26505995 [TBL] [Abstract][Full Text] [Related]
38. MicroRNA-302b-3p Suppresses Cell Proliferation Through AKT Pathway by Targeting IGF-1R in Human Gastric Cancer. Guo B; Zhao Z; Wang Z; Li Q; Wang X; Wang W; Song T; Huang C Cell Physiol Biochem; 2017; 42(4):1701-1711. PubMed ID: 28743112 [TBL] [Abstract][Full Text] [Related]
39. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer. Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822 [TBL] [Abstract][Full Text] [Related]
40. Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia. Lee TW; Wong WW; Dickson BD; Lipert B; Cheng GJ; Hunter FW; Hay MP; Wilson WR Int J Radiat Biol; 2019 Dec; 95(12):1597-1612. PubMed ID: 31490091 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]